MDNA132 / Medicenna - LARVOL DELTA

Characterization of MDNA132, an IL-13 decoy receptor selective superkine for targeted delivery of immunotherapies to the tumor microenvironment (AACR 2023) - "MDNA132 is an engineered IL13Rα2 selective superkine that accumulates in TME of IL13Rα2 expressing tumors in mice. MDNA109FEAA-Fc-MDNA132 and anti-PD1-MDNA132 retain their respective receptor binding profile, IL2R agonism and PD1/PDL1 blockade illustrating the versatilityof MDNA132 BiSKIT platform for targeted delivery of a broad range of therapeutic and/or immune-modulatory agents to tumors overexpressing the IL13α2 decoy receptor."

Biomarker • IO biomarker • Tumor microenvironment • Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • IL13 • IL13RA2 • IL4R

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting (GlobeNewswire) - "The data presented at AACR demonstrates the ability of our IL-13 Superkines to preferentially accumulate in the microenvironment of IL-13Rα2-expressing tumors, enabling development of first-in-class precision immunotherapies that can selectively deliver a variety of therapeutic payloads....The AACR poster includes data demonstrating that both MDNA132 and MDNA213 exhibit highly selective binding to the IL-13 decoy receptor (IL-13Rα2) and, in a murine model, selectively accumulate in the tumor microenvironment (TME) for several days."

Preclinical • Oncology • Solid Tumor

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting (GlobeNewswire) - "Medicenna Therapeutics Corp...announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023....The poster will describe preclinical studies characterizing a long-acting version of MDNA132 and BiSKITs™, (Bifunctional SuperKine ImmunoTherapies) comprising MDNA132 fused to an IL-2 super-agonist or anti-PD1 antibody. MDNA132 is an IL-13 Superkine designed to enable targeted delivery of immunotherapies to the tumor microenvironment."

Preclinical • Oncology • Solid Tumor

MDNA132 is an IL-13 Superkine selective to IL-13Rα2 with broadpotential for delivery of immunotherapies to the tumormicroenvironment (AACR-NCI-EORTC 2022) - "MDNA132-based BiSKITs retain receptor binding profileand biological function of both MDNA132 and the fusion partner. MDNA132localizes preferentially to IL-13Rα2 tumors in mice. These data highlight theversatility of MDNA132 and its potential to localize delivery of immunotherapeutics to the TME of cancers expressing IL-13Rα2."

Biomarker • Tumor microenvironment • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IL13 • IL13RA2 • IL4